ID NOW is a rapid, respiratory molecular testing platform that delivers accurate results in just minutes, so you can make diagnostic decisions during the first patient visit. ID NOW provides diagnostic results where and when you need them — in near-patient settings at the point of care.
The ID NOW Platform allows lab directors to maintain high diagnostic quality, while empowering clinicians to make faster decisions with diagnostic results in real time.
With ID NOW you can test for COVID-19, influenza, RSV, and strep A on one platform. With the platform's flexibility, you can base your testing on prevalence and other available clinical parameters, which allows you to eliminate unnecessary tests and thereby achieve increased testing accuracy and clinical certainty.
The ID NOW Platform gives you the flexibility to test for COVID-19 only or test for COVID-19 and influenza A & B using a single patient swab. With positive COVID-19 results in as few as 6 minutes, or results for both COVID-19 and influenza A & B within 15 – 22 minutes, ID NOW improves patient management and helps control the spread of disease.
ID NOW is the fastest rapid molecular solution available, with accurate positive results in 6 minutes or faster.1 Using rapid nucleic acid amplification technology (NAAT), it offers RT-PCR equivalent results in real-time, without compromising quality—giving you immediate answers to make patient management decisions in the moment.
Testing with the ID NOW Platform is designed for intuitive use and supported by on-screen guidance at every step, requiring minimal training to operate the platform. Plus, the assay kits contain all the components you need without requiring refrigeration, so you can test on demand right out of the box when and where needed.
ID NOW connects seamlessly to existing patient data management infrastructure to reliably connect the diagnostic and patient management pathways, improving workflows.
Based on your current location, the content on this page may not be relevant for your country.